Tyra Biosciences

Company snapshot

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables the rapid and precise refinement of structural drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 17 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tyra Biosciences. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Tyra Biosciences.

1. Jun 8, 2026 Clinical update

   TYR200-101 — Phase 1

2. Jun 8, 2026 Clinical update

   TYR300-101 — Phase 2

3. Jun 8, 2026 Clinical update

   TYR300-202 — Phase 2

4. May 23, 2026 Clinical update

   Dabogratinib (TYRA-300) 60mg — Phase 2

5. May 23, 2026 Clinical update

   TYRA-300 — Phase 2

View all clinical trial activity →

• What is Tyra Biosciences?

  Tyra Biosciences is a pharma organization headquartered in Carlsbad, USA. It trades on NYSE under ticker TYRA. Primary therapeutic focus areas include Non-muscle invasive bladder cancer (NMIBC), Low Grade Upper Tract Urothelial Carcinoma, Locally Advanced Cholangiocarcinoma, Acho

• Is Tyra Biosciences publicly traded?

  Yes. Tyra Biosciences is listed with ticker TYRA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Tyra Biosciences develop or market?

  We link 3 drug profile(s) where Tyra Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tyra-biosciences#company-drugs.

• What are the latest developments for Tyra Biosciences?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tyra Biosciences focus on?

  Tyra Biosciences focuses on Non-muscle invasive bladder cancer (NMIBC), Low Grade Upper Tract Urothelial Carcinoma, Locally Advanced Cholangiocarcinoma based on our analysis of their pipeline programs and drug development activities.